Purdue Pharma and Napp Pharmaceutical have filed a patent infringement petition against Sun Pharmaceuticals and its US subsidiary. The litigation was filed following a para IV certification filed by the Purdue to manufacture and market generic version of the Napp’s Ryzolt – tramadol hydrochloride, a pain killer.
The complaint is filed in the US District Court of Delaware, Which alleges that the defendants’ move to launch the generic version will infringe the US patents, under Patent Nos 6254887 for controlled release tramadol, and 7074430 controlled release tramadol tramadol [sic] formulation, reported Pharmabiz.
The complaint is filed against Sun Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Inc, Sun Pharma Global FZE and Caraco Pharmaceutical Laboratories Ltd. The patents in litigation are valid till May 2014.